Palermo Giuseppe, Totaro Angelo, Sacco Emilio, Foschi Nazario, Gulino Gaetano, Racioppi Marco, Bassi Pierfrancesco, Pinto Francesco
Department of Urology, Sacro Cuore Catholic University, A. Gemelli University Hospital, Rome, Italy.
Minerva Urol Nefrol. 2017 Feb;69(1):93-100. doi: 10.23736/S0393-2249.16.02696-5. Epub 2016 Sep 28.
Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer death in developed countries. Despite the primary treatments, 20-30% of patients experience a recurrence. The main objective of this study was to evaluate the clinical efficacy of salvage high intensity focused ultrasound (HIF U) after radical prostatectomy in terms of biochemical free survival rate (BFSR) and PSA nadir.
Twenty two patients with local recurrence of Pca after radical prostatectomy underwent HIFU as first-line salvage therapy. Considering that in all HIFU experiences, PSA nadir and PSA failure are different and PSA definition of BFSR is unknown, we defined treatment success as a PSA nadir ≤0.4 ng/mL 3 months after treatment. All early and late medical and surgical complications were recorded.
Ten of the 22 patients (45.5%) were classified as "success" three months after HIFU, showing a nadir PSA≤0.4 ng/mL; 12/22 patients (54.5%) were classified as "failure" during follow-up (median follow-up: 48 months). Seventeen of 22 (77%) patients were continent (no-pad) before HIFU. A new diagnosis of stress urinary incontinence was made in 5 cases (early onset) after treatment. A case of vesicoureteral anastomotic stenosis was treated, endoscopically through cold urethrotomy. We did not observe cases of recto-urinary fistula or persistent lower urinary tract symptoms. Two sevenths of the patients complained about de novo erectile dysfunction after HIFU.
The positive oncologic outcomes in the short term anyway obtained in selected patients, associated with documented mild side effects, represent the basis to start more organic, prospective, randomized and multicenter study protocols, that with a long term follow-up could confirm these promising preliminary results.
前列腺癌(PCa)是男性中最常被诊断出的恶性肿瘤,在发达国家是癌症死亡的第二大主要原因。尽管进行了初步治疗,但仍有20%-30%的患者会复发。本研究的主要目的是根据生化无复发生存率(BFSR)和PSA最低点,评估根治性前列腺切除术后挽救性高强度聚焦超声(HIFU)的临床疗效。
22例根治性前列腺切除术后局部复发的PCa患者接受了HIFU作为一线挽救治疗。鉴于在所有HIFU治疗经验中,PSA最低点和PSA失败情况各不相同,且BFSR的PSA定义尚不清楚,我们将治疗成功定义为治疗后3个月时PSA最低点≤0.4 ng/mL。记录所有早期和晚期的医疗及手术并发症。
22例患者中有10例(45.5%)在HIFU治疗3个月后被归类为“成功”,其PSA最低点≤0.4 ng/mL;12/22例患者(54.5%)在随访期间(中位随访时间:48个月)被归类为“失败”。22例患者中有17例(77%)在HIFU治疗前控尿(无需使用尿垫)。治疗后有5例(早期发生)被新诊断为压力性尿失禁。1例膀胱输尿管吻合口狭窄通过冷尿道切开术进行了内镜治疗。我们未观察到直肠尿道瘘或持续性下尿路症状的病例。七分之二的患者在HIFU治疗后抱怨出现了新发勃起功能障碍。
无论如何,在部分患者中短期内获得的积极肿瘤学结果,以及记录在案的轻微副作用,为启动更全面、前瞻性、随机和多中心研究方案奠定了基础,通过长期随访有望证实这些有前景的初步结果。